Cell-surface terminal galactose glycans

Cell-surface terminal galactose glycans are carbohydrate motifs located at the distal ends of glycan chains on glycoproteins and glycolipids. These residues are typically masked by terminal sialic acids in healthy tissues but become exposed through enzymatic desialylation or aberrant glycosylation pathways. The exposure of terminal galactose serves as a primary biological signal for the clearance of glycoproteins from the blood by the asialoglycoprotein receptor (ASGPR) in the liver (PubMed: 11514513). In oncology, specific terminal galactose structures, most notably the Thomsen-Friedenreich (TF) antigen, are frequently overexpressed and facilitate tumor cell adhesion to the vascular endothelium during metastasis (NCBI: PMC3101318). These glycans are utilized as therapeutic targets for the delivery of cytotoxic agents via lectins or for immune-targeting using monoclonal antibodies. Additionally, they serve as important diagnostic biomarkers, where their presence can be detected using specialized carbohydrate-binding proteins like Peanut Agglutinin (PNA). Therapeutic strategies targeting these glycans must account for their presence in the liver to avoid unintended hepatotoxicity or rapid systemic clearance.

Other names

Terminal galactose residuesAsialoglycansDesialylated glycansGalactose-terminated glycansThomsen-Friedenreich antigenTF antigenβ-galactoside residues

Binding to terminal galactose residues facilitates receptor-mediated endocytosis via the asialoglycoprotein receptor (ASGPR) for targeted drug delivery or serves as an antigenic site for monoclonal antibody-mediated therapy.